시장보고서

상품코드

1587544

과민성대장증후군 치료 시장 규모, 점유율, 분석 보고서 : 유형별, 제품별, 유통 채널별, 지역별, 부문별 예측(2025-2030년)

Irritable Bowel Syndrome Treatment Market Size, Share & Analysis Report By Type (IBS-C, IBS-D), By Product (Xifaxan, Linzess/Constella, Viberzi, Amitiza), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

발행일: 2024년 10월 | 리서치사:

Grand View Research | 페이지 정보: 영문 100 Pages | 배송안내 : 2-10일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

과민성대장증후군 치료 시장 성장 및 동향:

Grand View Research, Inc.의 최신 보고서에 따르면 과민성대장증후군 치료 세계 시장 규모는 2025년부터 2030년까지 연평균 8.8% 성장하여 2030년에는 60억 2,000만 달러에 달할 것으로 예상됩니다.

대상 질환의 유병률 증가와 기존 약물의 적응증 확대가 시장 성장을 가속화할 가능성이 높습니다. 또한, 약물의 보급과 신제품 출시가 과민성대장증후군(IBS) 치료제 시장을 견인할 것으로 예상됩니다.

IBS는 가장 흔한 위장병 중 하나이며, 전 세계 유병률은 보통 10-15%입니다. IBS 환자의 대부분은 50세 미만이지만, 노인들도 많이 앓고 있습니다. 증상의 영향은 경미한 불편함에서 심각한 쇠약에 이르기까지 다양하며, IBS는 환자의 업무, 감정 및 사회 생활의 다양한 측면을 지배 할 수 있습니다. 중등도에서 중증의 환자는 일반적으로 정서적, 신체적, 교육적, 사회적, 경제적 안녕을 자주 손상시키는 증상과 싸우고 있습니다.

증상은 다양하며 때로는 변비와 설사가 번갈아 가며 때로는 모순되기도 합니다. 장기적인 증상은 환자의 업무 및 개인 활동을 방해하고 일반적으로 개인의 잠재력을 제한합니다. 이러한 요인으로 인해 과민성대장증후군 치료의 필요성이 더욱 높아져 환자가 규칙적인 생활을 할 수 있습니다.

IBS 환자의 약 40%는 경증, 35%는 중등도 IBS, 25%는 중증 IBS이며, IBS 증상을 구분하지 못하는 사람이 상당히 많기 때문에 IBS는 여전히 의사가 진단하는 가장 흔한 질환 중 하나이며, IBS 증상이 있는 모든 사람이 치료를 받는 것은 아닙니다. 하지만 미국에서만 연간 240만-350만 명이 과민성대장증후군으로 병원을 찾습니다. 전 세계적으로 남성의 약 35-40%, 여성의 약 60-65%가 과민성대장증후군을 앓고 있습니다.

과민성대장증후군 치료 시장 보고서 하이라이트

IBS-C 분야는 유병률 증가와 린제스(리나크로티드), 아미티자(루비프로스톤)와 같은 효과적인 약물의 채택 증가로 인해 예측 기간 동안 CAGR 11.9%로 성장할 것으로 예상됩니다.
IBS-D 영역은 진단 사례의 증가와 삶의 질에 미치는 영향에 대한 이해도가 높아지면서 2024년 49.8%의 최대 매출 점유율로 시장을 장악했습니다.
Linzese/Constella가 2024년 37.3%의 최대 매출 점유율을 차지하며 시장을 석권했습니다.
병원 약국은 2024년 가장 큰 매출 점유율을 차지하며 시장을 주도했습니다. 이는 종합적인 인프라와 통합된 환자 관리 시스템 덕분입니다.
북미 과민성대장증후군(IBS) 치료 시장은 2024년 37.5%의 가장 큰 매출 점유율을 차지하며 세계 시장을 장악했습니다.
유럽 과민성대장증후군 치료 시장의 성장은 소화기 질환의 오명을 벗기 위한 인식 개선 캠페인의 증가에 힘입어 성장하고 있습니다. 독일과 영국과 같은 국가에서는 IBS 증상과 가능한 치료법에 대한 환자들의 참여가 증가하고 있습니다.

지역별 시장 점유율 분석, 2024년 및 2030년
지역 시장 대시보드
시장 규모, 예측 동향 분석, 2018년에서 2030년 :
북미
- 미국
- 캐나다
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
아시아태평양
- 중국
- 일본
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카공화국

제8장 경쟁 상황

참여자 개요
기업의 시장 포지션 분석
기업 분류
전략 매핑
기업 개요
- Ironwood Pharmaceuticals, Inc.
- Allergan
- Astellas Pharma, Inc.
- Takeda Pharmaceutical Company Limited
- AstraZeneca
- Sanofi SA
- Sebela Pharmaceuticals Inc
- Bausch Health
- Synthetic Biologics, Inc
- Ardelyx

ksm 24.11.21

Irritable Bowel Syndrome Treatment Market Growth & Trends:

The global irritable bowel syndrome treatment market size is expected to reach USD 6.02 billion by 2030, registering a CAGR of 8.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. Rising prevalence of target disease and increasing label extension of existing drugs are likely to accelerate market growth. In addition, growing uptake of drugs and launch of novel products are anticipated to drive the irritable bowel syndrome (IBS) treatment market.

IBS is one of the most common gastrointestinal disorders, with the worldwide prevalence rate usually ranging between 10-15%. Most of the patients with IBS are under 50 years of age but many older adults suffer as well. The effect of the condition can vary from mild inconvenience to serious debilitation. It can control many facets of a patient's professional, emotional, and social life. Patients with moderate to severe conditions usually struggle with symptoms that frequently impair their emotional, physical, educational, social, and economic wellbeing.

Symptoms can vary and are sometimes contradictory, constipation can alternate with diarrhea. Long-term symptoms can disturb the patient's professional and personal activities, and usually limits an individual's potential.These factors further increase the need for irritable bowel syndrome treatment, which enable patients to go on with their regular life.

Around 40% patients have mild IBS, 35% have moderate IBS, and 25% have severe IBS. A significant number of people cannot distinguish IBS symptoms; it is still one of the most common disorders diagnosed by physicians. Not everyone with IBS symptoms pursues treatment for the same. Though, there are around 2.4-3.5 million yearly doctor visits for irritable bowel syndrome in U.S. alone. Globally, it affects around 35-40% of males and 60-65% of females.

Irritable Bowel Syndrome Treatment Market Report Highlights:

The IBS-C segment is expected to grow at a CAGR of 11.9% over the forecast period, owing to the increasing prevalence of this condition and the rising adoption of effective medications such as Linzess (linaclotide) and Amitiza (lubiprostone).
The IBS-D segment dominated the market with the largest revenue share of 49.8% in 2024 attributed to a rise in diagnosed cases and an increasing understanding of the condition's impact on quality of life.
Linzess/Constella dominated the market and accounted for the largest revenue share of 37.3% in 2024 attributed to its effectiveness in managing constipation-predominant IBS (IBS-C).
Hospital pharmacies led the market and accounted for the largest revenue share in 2024, which is attributed to their comprehensive infrastructure and integrated patient care systems.
North America irritable bowel syndrome (IBS) treatment market dominated the global market and accounted for the largest revenue share of 37.5% in 2024 attributed to the high prevalence of IBS and the increasing awareness of its management options.
The growth of Europe irritable bowel syndrome treatment market is driven by increasing awareness campaigns aimed at destigmatizing gastrointestinal disorders. Countries such as Germany and the UK are seeing increased patient engagement regarding IBS symptoms and available treatments.

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
- 1.3.1. Information Procurement
- 1.3.2. Information or Data Analysis
- 1.3.3. Market Formulation & Data Visualization
- 1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1. List of Data Sources

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Irritable Bowel Syndrome Treatment Market Variables, Trends, & Scope

3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
- 3.3.1. Market Drivers Analysis
- 3.3.2. Market Restraints Analysis
3.4. Irritable Bowel Syndrome Treatment Market Analysis Tools
- 3.4.1. Porter's Analysis
  - 3.4.1.1. Bargaining power of the suppliers
  - 3.4.1.2. Bargaining power of the buyers
  - 3.4.1.3. Threats of substitution
  - 3.4.1.4. Threats from new entrants
  - 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
  - 3.4.2.1. Political landscape
  - 3.4.2.2. Economic and Social landscape
  - 3.4.2.3. Technological landscape
  - 3.4.2.4. Environmental landscape
  - 3.4.2.5. Legal landscape

Chapter 4. Irritable Bowel Syndrome Treatment Market: Type Estimates & Trend Analysis

4.1. Type Market Share, 2024 & 2030
4.2. Type Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
4.4. IBS-C
- 4.4.1. IBS-C Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. IBS-D
- 4.5.1. IBS-D Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Irritable Bowel Syndrome Treatment Market: Drug Class Estimates & Trend Analysis

5.1. Drug Class Market Share, 2024 & 2030
5.2. Drug Class Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
5.4. Xifaxan
- 5.4.1. Xifaxan Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Linzess/Constella
- 5.5.1. Linzess/Constella Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Viberzi
- 5.6.1. Viberzi Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. Amitiza
- 5.7.1. Amitiza Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.8. Others
- 5.8.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Irritable Bowel Syndrome Treatment Market: Distribution Channel Estimates & Trend Analysis

6.1. Distribution Channel Market Share, 2024 & 2030
6.2. Distribution Channel Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel , 2018 to 2030 (USD Million)
6.4. Hospital Pharmacy
- 6.4.1. Hospital Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Retail Pharmacy
- 6.5.1. Retail Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. Others
- 6.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Irritable Bowel Syndrome Treatment Market: Regional Estimates & Trend Analysis

7.1. Regional Market Share Analysis, 2024 & 2030
7.2. Regional Market Dashboard
7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.4. North America
- 7.4.1. North America Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.2. U.S.
  - 7.4.2.1. Key Country Dynamics
  - 7.4.2.2. Regulatory Framework
  - 7.4.2.3. Competitive Insights
  - 7.4.2.4. U.S. Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.3. Canada
  - 7.4.3.1. Key Country Dynamics
  - 7.4.3.2. Regulatory Framework
  - 7.4.3.3. Competitive Insights
  - 7.4.3.4. Canada Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Europe
- 7.5.1. Europe Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.2. UK
  - 7.5.2.1. Key Country Dynamics
  - 7.5.2.2. Regulatory Framework
  - 7.5.2.3. Competitive Insights
  - 7.5.2.4. UK Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.3. Germany
  - 7.5.3.1. Key Country Dynamics
  - 7.5.3.2. Regulatory Framework
  - 7.5.3.3. Competitive Insights
  - 7.5.3.4. Germany Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.4. France
  - 7.5.4.1. Key Country Dynamics
  - 7.5.4.2. Regulatory Framework
  - 7.5.4.3. Competitive Insights
  - 7.5.4.4. France Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.5. Italy
  - 7.5.5.1. Key Country Dynamics
  - 7.5.5.2. Regulatory Framework
  - 7.5.5.3. Competitive Insights
  - 7.5.5.4. Italy Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.6. Spain
  - 7.5.6.1. Key Country Dynamics
  - 7.5.6.2. Regulatory Framework
  - 7.5.6.3. Competitive Insights
  - 7.5.6.4. Spain Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Asia Pacific
- 7.6.1. Asia Pacific Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.2. China
  - 7.6.2.1. Key Country Dynamics
  - 7.6.2.2. Regulatory Framework
  - 7.6.2.3. Competitive Insights
  - 7.6.2.4. China Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.3. Japan
  - 7.6.3.1. Key Country Dynamics
  - 7.6.3.2. Regulatory Framework
  - 7.6.3.3. Competitive Insights
  - 7.6.3.4. Japan Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.7. Latin America
- 7.7.1. Latin America Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7.2. Brazil
  - 7.7.2.1. Key Country Dynamics
  - 7.7.2.2. Regulatory Framework
  - 7.7.2.3. Competitive Insights
  - 7.7.2.4. Brazil Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7.3. Argentina
  - 7.7.3.1. Key Country Dynamics
  - 7.7.3.2. Regulatory Framework
  - 7.7.3.3. Competitive Insights
  - 7.7.3.4. Argentina Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.8. Middle East and Africa
- 7.8.1. Middle East and Africa Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8.2. South Africa
  - 7.8.2.1. Key Country Dynamics
  - 7.8.2.2. Regulatory Framework
  - 7.8.2.3. Competitive Insights
  - 7.8.2.4. South Africa Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

8.1. Participant Overview
8.2. Company Market Position Analysis
8.3. Company Categorization
8.4. Strategy Mapping
8.5. Company Profiles/Listing
- 8.5.1. Ironwood Pharmaceuticals, Inc.
  - 8.5.1.1. Participant's Overview
  - 8.5.1.2. Financial Performance
  - 8.5.1.3. Product Benchmarking
  - 8.5.1.4. Recent Developments/ Strategic Initiatives
- 8.5.2. Allergan
  - 8.5.2.1. Participant's Overview
  - 8.5.2.2. Financial Performance
  - 8.5.2.3. Product Benchmarking
  - 8.5.2.4. Recent Developments/ Strategic Initiatives
- 8.5.3. Astellas Pharma, Inc.
  - 8.5.3.1. Participant's Overview
  - 8.5.3.2. Financial Performance
  - 8.5.3.3. Product Benchmarking
  - 8.5.3.4. Recent Developments/ Strategic Initiatives
- 8.5.4. Takeda Pharmaceutical Company Limited
  - 8.5.4.1. Participant's Overview
  - 8.5.4.2. Financial Performance
  - 8.5.4.3. Product Benchmarking
  - 8.5.4.4. Recent Developments/ Strategic Initiatives
- 8.5.5. AstraZeneca
  - 8.5.5.1. Participant's Overview
  - 8.5.5.2. Financial Performance
  - 8.5.5.3. Product Benchmarking
  - 8.5.5.4. Recent Developments/ Strategic Initiatives
- 8.5.6. Sanofi S.A
  - 8.5.6.1. Participant's Overview
  - 8.5.6.2. Financial Performance
  - 8.5.6.3. Product Benchmarking
  - 8.5.6.4. Recent Developments/ Strategic Initiatives
- 8.5.7. Sebela Pharmaceuticals Inc
  - 8.5.7.1. Participant's Overview
  - 8.5.7.2. Financial Performance
  - 8.5.7.3. Product Benchmarking
  - 8.5.7.4. Recent Developments/ Strategic Initiatives
- 8.5.8. Bausch Health
  - 8.5.8.1. Participant's Overview
  - 8.5.8.2. Financial Performance
  - 8.5.8.3. Product Benchmarking
  - 8.5.8.4. Recent Developments/ Strategic Initiatives
- 8.5.9. Synthetic Biologics, Inc
  - 8.5.9.1. Participant's Overview
  - 8.5.9.2. Financial Performance
  - 8.5.9.3. Product Benchmarking
  - 8.5.9.4. Recent Developments/ Strategic Initiatives
- 8.5.10. Ardelyx
  - 8.5.10.1. Participant's Overview
  - 8.5.10.2. Financial Performance
  - 8.5.10.3. Product Benchmarking
  - 8.5.10.4. Recent Developments/ Strategic Initiatives

과민성대장증후군 치료 시장 규모, 점유율, 분석 보고서 : 유형별, 제품별, 유통 채널별, 지역별, 부문별 예측(2025-2030년)

Irritable Bowel Syndrome Treatment Market Size, Share & Analysis Report By Type (IBS-C, IBS-D), By Product (Xifaxan, Linzess/Constella, Viberzi, Amitiza), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

과민성대장증후군 치료 시장 성장 및 동향:

과민성대장증후군 치료 시장 보고서 하이라이트

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 과민성대장증후군 치료 시장 변수, 동향, 범위

제4장 과민성대장증후군 치료 시장 : 유형 추정·동향 분석

제5장 과민성대장증후군 치료 시장 : 약물 종류 추정·동향 분석

제6장 과민성대장증후군 치료 시장 : 유통 채널 추정·동향 분석

제7장 과민성대장증후군 치료 시장 : 지역 추정·동향 분석